respiratori
syncyti
viru
rsv
member
genu
pneumoviru
classifi
famili
paramyxovirida
common
caus
sever
diseas
lower
respiratori
tract
infant
elderli
especi
develop
countri
also
report
claim
rsv
could
lead
sever
repeat
infect
recurr
wheez
pneumonia
asthma
later
childhood
worldwid
number
rsvassoci
case
estim
million
number
death
children
younger
year
old
spite
fact
number
lower
usa
due
precaut
rsv
besid
young
children
hospit
rate
elderli
peopl
year
old
may
influenza
case
rsv
vaccin
develop
effort
inactiv
rsv
liveattenu
rsv
subunit
vaccin
underway
howev
despit
five
decad
intens
research
develop
rsv
vaccin
approv
vaccin
drug
avail
instead
vaccin
research
attempt
develop
prophylact
antibodi
therapi
target
rsv
f
protein
antivir
drug
ribavirin
nucleosid
analog
target
hepat
c
virus
includ
rsv
new
nucleosid
analog
pyrazolo
pyrimidin
base
rsv
fusion
inhibitor
neutral
monoclon
antibodi
palivizumab
motavizumab
numax
administ
infant
high
risk
develop
respiratori
diseas
altern
expens
therapi
vaccin
confer
long
last
immun
less
expens
effici
option
recurr
rsv
infect
due
frequent
antigen
variat
rna
virus
rsv
influenza
viru
rhinoviru
develop
vaccin
complet
protect
challeng
incomplet
immun
respons
natur
rsv
infect
respons
repeat
infect
rsv
vaccin
studi
use
formalin
inactiv
rsv
firsv
consist
whole
viru
exacerb
diseas
even
case
result
death
elev
helper
mediat
immun
respons
addit
use
vector
express
rsv
antigen
found
far
safer
subunit
inactiv
rsv
immun
import
immunolog
respons
safe
stabl
vaccin
long
last
immun
urgent
need
public
outer
surfac
glycoprotein
fusion
f
attach
g
rsv
known
antigen
protein
induc
humor
cellular
immun
respons
target
antigen
present
cell
rsv
f
protein
mediat
fusion
viru
particl
host
merg
virion
envelop
host
cell
membran
follow
virion
attach
use
g
protein
addit
f
protein
facilit
fusion
neighbor
normal
cell
infect
cell
thu
creat
multinuclear
giant
cell
call
syncytia
character
rsv
infect
rsv
f
protein
highli
conserv
among
differ
rsv
strain
compar
rsv
protein
hand
variabl
g
amino
acid
sequenc
among
variou
rsv
strain
high
furthermor
previou
report
demonstr
rsv
f
vaccin
provid
protect
rsv
rsv
b
strain
produc
neutral
antibodi
wherea
rsv
g
vaccin
promin
induc
bias
immun
respons
therebi
enhanc
sever
diseas
subsequ
rsv
infect
helper
lymphocyt
activ
either
b
cell
produc
specif
antibodi
cytotox
lymphocyt
respons
clearanc
rsv
infect
cell
cellmedi
protect
immun
import
clearanc
infect
cell
howev
cellmedi
immun
suffici
provid
complet
protect
pathogen
therefor
necessari
memori
b
cell
activ
neutral
antibodi
upon
reinfect
although
dna
vaccin
highli
immunogen
compar
whole
pathogen
protein
vaccin
dna
vaccin
advantag
express
nativ
form
antigen
produc
vivo
induc
strong
b
cell
respons
chang
epitop
region
antigen
may
shift
immun
respons
lead
unwant
allerg
immun
reaction
seen
firsv
vaccin
trial
highli
immunogen
rsv
f
protein
conserv
sequenc
would
desir
dna
vaccin
candid
protect
repeat
rsv
infect
group
previous
develop
dna
vaccin
contain
immunogen
region
rsv
f
protein
residu
show
dna
vaccin
provid
partial
protect
balbc
mice
combin
cholera
toxin
adjuv
studi
develop
fulllength
rsv
f
dna
vaccin
abl
induc
predominantli
type
respons
without
use
adjuv
antibodi
respons
serum
significantli
enhanc
subsequ
immun
sera
immun
anim
abl
neutral
rsv
vitro
protect
afford
dna
vaccin
complet
thu
necessit
design
develop
method
vaccin
combinatori
concept
take
advantag
variou
vaccin
prime
vaccin
dna
vaccin
follow
booster
vaccin
subunit
recombin
protein
vaccin
may
lead
complet
protect
rsv
restrict
enzym
noti
bamhi
dna
ligas
eagl
minim
essenti
medium
mem
hank
balanc
salt
solut
hbss
fetal
bovin
serum
fb
lglutamin
mm
antibiot
electropor
kit
cell
taqman
master
mix
real
time
probe
primer
superscript
ii
revers
transcriptas
rnase
later
solut
obtain
life
carlsbad
ca
usa
dna
rna
isol
kit
purchas
valencia
ca
usa
mem
supplement
fb
penicillin
streptomycin
kanamycin
lglutamin
mm
human
epitheli
type
monkey
kidney
vero
cell
obtain
american
type
cultur
collect
atcctm
manassa
va
usa
balbc
femal
mice
week
old
purchas
charl
river
laboratori
wilmington
anim
hous
standard
approv
condit
cycl
h
light
h
dark
provid
daili
steril
food
water
ad
libitum
immun
studi
approv
protocol
alabama
state
univers
institut
anim
care
use
committe
follow
human
rsv
long
strain
purchas
american
type
cultur
collect
atcc
manassa
va
atcc
propag
cell
atcc
cell
grown
tissu
cultur
flask
mem
supplement
fb
antibiot
human
rsv
ad
cell
monolay
viru
adsorpt
carri
h
humidifi
atmospher
mem
fb
ad
flask
infect
cell
observ
addit
day
rsv
infect
cell
centrifug
remov
cellular
debri
aliquot
store
use
rsv
f
dna
sequenc
origin
publish
collin
et
al
fulllength
rsv
f
gene
synthes
epoch
lab
missouri
citi
tx
usa
amplifi
polymeras
chain
reaction
pcr
use
forward
revers
primer
shown
tabl
rsv
f
gene
dna
vector
digest
bamhi
noti
enzym
purifi
dna
piec
use
qiagen
gel
extract
kit
ligat
use
dna
ligas
enzym
transform
compet
cell
escherichia
coli
select
compet
cell
grown
kanamycin
supplement
luria
bertani
lb
agar
clone
contain
rsv
f
gene
vector
name
pf
figur
gfp
gene
amplifi
pcr
use
previous
publish
gfp
plasmid
vector
templat
forward
revers
primer
tabl
bamhi
noti
restrict
site
respect
amplifi
gfp
gene
insert
vector
follow
protocol
condit
describ
clone
contain
gfp
gene
vector
name
pg
third
vector
contain
rsv
f
gfp
also
clone
name
pfg
figur
b
vector
purifi
use
qiagen
endofre
giga
kit
purifi
dna
vector
aliquot
store
use
lonza
germani
electropor
protocol
use
vitro
gene
transfect
follow
manufactur
instruct
cell
use
nucleofector
ii
electropor
devic
lonza
germani
gfp
label
rsv
f
gene
construct
use
immunofluoresc
imag
flow
cytometri
wherea
rsv
f
gene
construct
use
rtpcr
analysi
transfect
cell
rsv
f
dna
incub
day
allow
protein
express
vitro
incub
time
imag
show
protein
express
green
color
taken
use
immunofluoresc
microscop
also
cell
use
flow
cytometri
detect
green
fluoresc
gfp
label
rsv
f
protein
transfect
express
protocol
follow
describ
rsv
f
dna
detect
rsv
f
mrna
rtpcr
order
analyz
transfect
effici
cell
transfect
pf
construct
use
nucleofector
electropor
gene
transfect
follow
manufactur
instruct
total
rna
isol
harvest
cell
rna
convert
cdna
use
superscript
revers
transcriptas
enzym
follow
manufactur
protocol
rsv
f
mrna
specif
primer
probe
experiment
protocol
qpcr
adapt
mentel
et
al
qpcr
reaction
carri
revers
forward
primer
tabl
use
appli
biosystem
viia
real
time
pcr
appli
biosystem
intern
foster
citi
ca
usa
qpcr
reaction
run
duplic
along
water
neg
control
dilut
rsv
f
gene
amplicon
copi
number
use
prepar
standard
curv
experi
repeat
twice
transfect
step
duplic
anim
studi
perform
accord
nation
institut
health
nih
bethesda
md
guidelin
follow
protocol
approv
alabama
state
univers
institut
anim
care
use
committe
anim
hous
standard
approv
condit
provid
daili
steril
food
water
ad
libitum
sixtoeightweekold
femal
balbc
mice
charl
river
laboratori
inc
wilmington
massachusett
immun
intramuscularli
im
pb
pf
dna
pb
thigh
muscl
day
rsv
control
group
immun
intranas
plaqu
form
unit
pfu
live
rsv
long
strain
twice
day
day
slow
applic
nasal
nare
serum
collect
via
retroorbit
bleed
group
mice
day
determin
rsv
specif
antibodi
respons
saliva
collect
inject
carbachol
intraperiton
day
sera
collect
serum
saliva
sampl
store
analysi
sera
saliva
sampl
collect
mice
analyz
antibodi
respons
isotyp
analyz
antirsv
fspecif
antibodi
respons
elisa
plate
coat
uvinactiv
rsv
pfuwel
carbon
buffer
ph
incub
overnight
humidifi
atmospher
plate
block
milk
powder
incub
sampl
room
temperatur
hour
goat
antimous
hrpconjug
secondari
antibodi
dilut
specif
isotyp
iga
ad
elisa
plate
incub
room
temperatur
hour
elisa
plate
wash
enzymat
reaction
develop
absorb
read
nm
use
tecan
elisa
reader
tecan
research
triangl
park
nc
usa
viral
neutral
assay
mice
sera
sampl
perform
accord
protocol
singh
et
al
slight
modif
briefli
heat
inactiv
sera
min
per
well
group
mice
pb
rsv
rsv
f
dna
mix
pfu
rsv
incub
hour
approxim
cell
mix
serarsv
mixtur
plate
follow
incub
incub
day
cell
alon
cell
infect
rsv
pfu
use
neg
posit
control
respect
cell
wash
pb
ph
fix
cell
incub
aceton
vv
minut
elisa
assay
plate
block
milk
incub
primari
antibodi
goat
antirsv
dilut
secondari
antibodi
rabbit
antigoat
igghrp
dilut
room
temperatur
hour
plate
wash
enzymat
reaction
develop
tmb
substrat
kpl
gaithersburg
maryland
usa
follow
read
absorb
nm
elisa
reader
tecan
us
inc
durham
nc
usa
protocol
follow
immunofluoresc
microscopi
analysi
except
secondari
antibodi
rabbit
antigoat
iggfitc
dilut
cell
nuclei
stain
antifadedapi
merg
imag
taken
use
fitc
dapi
channel
immunofluoresc
microscop
nikon
eclips
ti
nikon
instrument
inc
melvil
usa
qpcr
elisa
viru
neutral
assay
data
present
mean
standard
deviat
statist
analysi
data
perform
use
sigma
plot
version
systat
softwar
inc
germani
differ
mean
four
experiment
group
determin
use
oneway
analysi
varianc
anova
tukey
test
signific
level
rsv
f
gene
clone
vector
bamhi
noti
restrict
enzym
site
posit
clone
verifi
digest
bamhi
noti
dna
sequenc
recombin
clone
contain
rsv
f
gene
vector
name
pf
test
express
effici
rsv
f
protein
express
vitro
rsv
f
gene
contain
gfp
gene
similarli
clone
vector
gener
pfg
clone
pf
pfg
clone
use
transfect
cell
three
day
transfect
green
fluoresc
signal
analyz
figur
c
pg
clone
show
high
level
gfp
protein
express
figur
b
pfg
vector
express
rsv
f
gfp
protein
figur
c
although
much
lower
level
compar
pg
clone
transfect
cell
trypsin
protein
express
detect
flow
cytometri
figur
f
transfect
effici
pg
clone
figur
e
effici
pfg
clone
rsv
fgfp
figur
f
compar
neg
clone
addit
immunofluoresc
flow
cytometri
analys
transcript
effici
pf
pfg
clone
quantifi
qpcr
analysi
cell
use
rsv
f
specif
primer
figur
rsv
f
mrna
copi
number
clone
pf
pfg
significantli
higher
compar
rsv
f
mrna
copi
number
neg
control
mock
transfect
cell
thu
confirm
use
three
differ
method
pf
clone
express
rsv
f
protein
vitro
humor
immun
respons
induc
immun
mice
pb
rsv
f
dna
vaccin
rsv
determin
measur
rsv
specif
serum
saliva
antibodi
titer
use
elisa
serum
saliva
sampl
collect
balbc
mice
interv
follow
immun
anim
vaccin
rsv
f
dna
rsv
show
significantli
higher
p
amount
serum
igg
level
compar
pb
neg
control
group
figur
saliva
sampl
group
show
signific
rsv
specif
igg
antibodi
respons
except
saliva
sampl
rsv
vaccin
mice
collect
day
data
shown
rsv
specif
igm
antibodi
detect
serum
sampl
saliva
rsv
f
immun
mice
immun
period
figur
b
igm
basic
immunoglobulin
produc
b
cell
first
antibodi
produc
respons
initi
exposur
antigen
sinc
immun
respons
import
provid
protect
immun
rsv
infect
also
analyz
compar
specif
immun
respons
antibodi
isotyp
serum
sampl
show
signific
level
figur
figur
b
figur
c
antibodi
day
immun
level
continu
increas
day
day
rsv
infect
mice
rsv
f
dna
immun
mice
product
stimul
day
product
detect
serum
sampl
isotyp
antibodi
respons
specif
mediat
respons
significantli
higher
immun
ratio
calcul
tabl
ratio
constantli
lower
clearli
demonstr
respons
follow
either
rsv
infect
rsv
f
vaccin
respons
promin
rsv
infect
rsv
f
dna
immun
mice
day
time
antibodi
level
highest
also
test
efficaci
serum
antibodi
neutral
rsv
infect
vitro
use
elisa
elisa
data
indic
rsv
specif
neutral
antibodi
rsv
f
dna
immun
mice
serum
reduc
infect
rsv
serum
dilut
serum
dilut
respect
figur
consist
serum
rsv
infect
mice
show
higher
rsv
reduct
serum
dilut
serum
dilut
respect
data
neutral
assay
accord
antibodi
respons
data
also
elisa
data
rsv
neutral
confirm
immunofluoresc
assay
experi
repeat
condit
reduct
rsv
infect
visual
decreas
fitc
signal
immunofluoresc
microscopi
figur
rsv
infect
visibl
observ
cell
incub
serum
pb
mice
compar
untreat
cell
figur
b
intens
fitc
signal
pb
group
detect
strong
posit
control
without
serum
wherea
green
signal
observ
cell
incub
rsvserum
rsv
infect
mice
figur
c
hand
rsv
immun
serum
consider
neutral
rsv
infect
cell
insignific
green
signal
detect
figur
e
immunofluoresc
microscopi
observ
confirm
result
elisa
neutral
assay
antibodi
respons
data
pathogen
infect
rsv
initi
activ
innat
respons
subsequ
develop
cellular
humor
immun
cellular
immun
need
clear
infect
wherea
humor
immun
respons
antibodi
mediat
requir
protect
initi
subsequ
rsv
infect
vaccin
perform
firsv
suggest
firsv
immun
lead
predomin
type
allerg
respons
wherea
wild
type
rsv
activ
helper
type
skew
immun
provid
protect
rsv
diseas
thu
type
immun
respons
desir
protect
natur
rsv
infect
understand
mechan
type
immun
respons
firsv
immun
differ
anim
model
monkey
bovin
mice
cotton
rat
test
model
challeng
wt
rsv
follow
immun
firsv
stimul
type
allerg
respons
contrast
anim
immun
challeng
wt
rsv
develop
type
antibodi
protect
rsv
likewis
natur
rsv
infect
produc
mediat
immun
respons
rsv
howev
desir
immun
kind
pathogen
balanc
respons
even
though
exact
mechan
firsv
mediat
enhanc
diseas
fulli
understood
murphi
et
al
suggest
formalin
treatment
alter
protect
epitop
f
g
protein
fail
produc
neutral
antibodi
real
rsv
infect
also
report
sera
firsv
immun
recipi
neutral
rsv
vitro
due
lack
rsv
specif
neutral
antibodi
compar
sera
wt
rsv
immun
recipi
consequ
nativ
form
rsv
f
requir
produc
neutral
antibodi
provid
immun
rsv
infect
dna
vaccin
thought
advantag
due
process
antigen
nativ
form
eukaryot
cell
due
effici
present
antigen
antigen
present
cell
thu
antibodi
produc
recombin
antigen
express
target
host
would
easili
recogn
nativ
nondenatur
protein
pathogen
provid
effici
specif
protect
real
pathogen
compar
recombin
protein
vaccin
express
bacteria
previou
studi
develop
dna
vaccin
contain
region
rsv
f
amino
acid
conjug
modifi
cholera
toxin
gene
use
immun
mice
result
higher
immun
respons
mention
firsv
vaccin
trial
nativ
form
rsv
f
protein
crucial
stimul
protect
immun
respons
rsv
major
structur
chang
rsv
f
protein
may
lead
diseas
exacerb
allerg
outcom
rsv
f
dna
vaccin
prefer
immunogen
compar
recombin
rsv
f
protein
produc
ex
vivo
dna
vaccin
intramuscular
inject
rout
best
rout
ensur
antigen
express
nativ
conform
besid
nativ
structur
anoth
advantag
dna
vaccin
elicit
bias
immun
respons
due
endogen
express
present
immun
cell
favor
respons
protect
pathogen
immun
system
product
neutral
antibodi
import
protect
reinfect
confer
long
term
immun
recruit
memori
b
cell
host
encount
pathogen
memori
b
cell
abruptli
produc
pathogen
specif
neutral
antibodi
immedi
inactiv
pathogen
enter
host
start
infect
test
abil
serum
collect
rsv
f
immun
mice
neutral
rsv
vitro
previou
studi
shown
serum
firsv
infect
mice
neutral
rsv
infect
due
alter
structur
rsv
f
protein
base
previou
studi
distinct
administr
rout
dna
vaccin
evok
differ
type
immun
respons
studi
design
base
previou
dna
vaccin
studi
intramuscular
inject
dna
vaccin
stimul
moder
cell
respons
antibodi
product
compar
oral
administr
induc
strong
cell
respons
weak
antibodi
respons
rsv
vaccin
develop
hamper
failur
previou
vaccin
trial
led
death
children
main
immunolog
event
respons
failur
vaccin
induct
predomin
respons
enhanc
rsv
diseas
follow
natur
infect
studi
aim
develop
safe
dna
vaccin
induc
mediat
antibodi
respons
studi
provid
basi
futur
rsv
vaccin
develop
could
benefit
dna
vaccin
design
may
consid
combin
dna
vaccin
immun
follow
tradit
recombin
vaccin
immun
higher
protect
rsv
infect
